

17p11.2

## Clinical and Electrophysiological Features of HNPP Patients with 17p11.2 Deletion

Yoon-Ho Hong, M.D, Manho Kim, M.D, Ph.D., Jung-Joon Sung, M.D,  
Sung Hun Kim, M.D, Ph.D.\*, Kwang-Woo Lee, M.D, Ph.D.

*Department of Neurology, and Clinical Research Institute in Seoul National University Hospital,  
College of Medicine, Seoul National University  
Department of Neurology in Kangwon National University Hospital\**

**Objectives** : Although the diagnosis of hereditary neuropathy with liability to pressure palsies (HNPP) is important for correct prognostic evaluation and genetic counseling, the diagnosis is frequently missed or delayed. Our main aim on undertaking this study was to characterize the electrodiagnostic features of HNPP.

**Material and Methods** : Clinical, electrophysiologic and molecular studies were performed on Korean HNPP patients with 17p11.2 deletion. The results of electrophysiologic studies were compared with those of Charcot-Marie-Tooth disease type 1A (CMT1A) patients carrying 17p11.2 duplication.

**Results** : Eight HNPP (50 motor, 39 sensory nerves) and six CMT1A (28 motor, 16 sensory nerves) patients were included. The slowing of sensory conduction in nearly all nerves and the distal accentuation of motor conduction abnormalities are the main features of background polyneuropathy in HNPP. In contrast to CMT1A, where severity of nerve conduction slowing was not different among nerve groups, HNPP sensory nerve conduction was more slowed in the median and ulnar nerves than in the sural nerve ( $p < 0.01$ ), and DML was more prolonged in the median nerve than in the other motor nerves ( $p < 0.01$ ). TLIs were significantly lower in HNPP than in the normal control and CMT1A patients for the median and ulnar nerves ( $p < 0.01$ ), and were also significantly reduced for the peroneal nerve ( $p < 0.05$ ) compared with those of the normal controls.

**Conclusion** : The distribution and severity of the background electrophysiologic abnormalities are closely related to the topography of common entrapment or compression sites, which suggests the possible pathogenetic role of subclinical pressure injury at these sites in the development of the distinct background polyneuropathy in HNPP.

**Key Words** : Hereditary neuropathy with liability to pressure palsies (HNPP), Charcot-Marie-Tooth disease type IA (CMT1A), Polymerase chain reaction (PCR), Polyneuropathy.

ropathy with liability to pressure palsies, HNPP)

가

(hereditary neu -

PMP22(peripheral myelin protein 22)

17 (17p11.2) 1.5 Mb

DNA

Charcot - Marie - Tooth disease type 1A(CMT1A)

Address for correspondence

**Kwang-Woo Lee, M.D., Ph.D.**

Department of Neurology,

Seoul National University Hospital

28 Yongon-Dong Chongno-gu, Seoul 110-744, Korea

Tel : +82-2-760-3215, Fax : +82-2-3672-7553

E-mail: kwoo@plaza.snu.ac.kr

(unequal crossover during meiosis)


(demyelinating neuropathies) (polymerase chain reaction, PCR) 17  
 (17p11.2) HNPP 8  
 HNPP CMT1A  
 CMT1A, HNPP  
 (entrapment) CMT1A  
 HNPP<sup>3-8</sup>  
 2000 11 2001 12  
 HNPP가 (5  
 가 )  
 가 , 22 가 (80%), 8  
 HNPP (17p11.2)  
 (Age range, 13-44 yrs; Female:Male, 3:5). 8  
 CMT1A 6  
 (Age range, 5-50 yrs; Female:  
 Male, 1:5).  
 HNPP  
 tomacu-  
 가 HNPP  
 31.0  
 HNPP (distal motor latency, DML),  
 (motor nerve conduction veloci-  
 ty, MNCV) F (F-wave latency),  
 (asymptomatic carriers) 가 (sensory  
 (sporadic cases) 가 nerve conduction time, SNCV) DML  
 HNPP<sup>12</sup> 가<sup>13</sup>  
 가  
 가 5 cm,  
 가 8 cm, 10 cm

**Table 1.** Clinical findings in eight HNPP patients with 17p11.2 deletion.

Patient	Relation	Sex	Age (yr)	Age at onset (yr)	Clinically affected nerve	Number of nerve palsy episodes
Family A						
patient 1	proband	Male	42	42	L. peroneal	1
patient 2	Brother	Male	39	20	R. radial	1
patient 3	Brother	Male	37	13	R. peroneal, R. radial	> 2
Family B						
patient 4	proband	Female	25	20	R. ulnar, R. radial	2
patient 5	Sister	Female	26			none
Family C						
patient 6	proband	Male	12	12	L. median	1
patient 7	Mother	Female	44			none
Family D						
patient 8	proband	Male	42	22	R. radial, Bil. ulnar	> 2



HNPP 50 (Fig. 2A). DML(% of ULN) CMT1A  
 39 , CMT1A 가  
 28 16 , HNPP  
 Table 2 . HNPP  
 SNCV (Kruskal-Wallis test,  $p < 0.01$ , Table 2) , DML  
 (97%). , SNCV (% of LLN) CMT1A , MNCV HNPP  
 가 , HNPP 가 (Fig. 2B).  
 MNCV  
 (Kruskal-Wallis test,  $p < 0.01$ , Table 2). (Sensory CMT1A 50%(25/50) MNCV 가  
 nerve action potential) CMT1A 50% 86% MNCV 가  
 (16/16), HNPP 33.3 % MNCV 가 90% , HNPP  
 (13/39) , MNCV 18% , MNCV 87.5%  
 DML HNPP (80%), CMT1A MNCV



**Figure 2.** Box plots of nerve conduction studies in HNPP and CMT1A for (A) distal motor latency (DML), (B) motor nerve conduction velocity (MNCV), (C) terminal latency indices (TLI) of all nerve groups, and (D) the TLI by individual nerve groups. All parameters except for TLI are expressed as the percentage of the relevant upper (ULN) or lower (LLN) limit of the normative values. Box plots are shown with 10<sup>th</sup>, 25<sup>th</sup>, 50<sup>th</sup>, 75<sup>th</sup>, and 90<sup>th</sup> percentile distributions and the values outside these limits are plotted as separate filled circles.

\*  $p < 0.01$ , ANOVA using Bonferroni multiple comparisons.

\*\*  $p < 0.01$ , Kruskal-Wallis tests.

\*\*\*  $p < 0.05$ , Mann-Whitney test.

MNCV (Mann-Whitney test,  $p < 0.02$ , Table 2). HNPP CMT1A, CMT1A 가 (TLI) TLI 가, HNPP MNCV HNPP 가 ( $p < 0.01$ , ANOVA using Bonferroni multiple comparisons, Fig. 2C). (spearman's  $\rho = 0.96$ ,  $p = 0.01$ ), HNPP (spearman's  $\rho = 0.07$ ,  $p = 0.8$ ). MNCV(% of LLN) HNPP TLI CMT1A 가 (Kruskal-Wallis test,  $p > 0.1$ ) (Kruskal-Wallis test,  $p < 0.01$ , Fig. 2D), in both conditions). CMAP CMT1A 82.1 (Mann-Whitney test,  $p < 0.05$ ), % (23/28), HNPP 6% (3/50)

**Table 2.** Electrophysiologic findings in HNPP and CMT1A patients.

	HNPP			CMT1A		
	N	Mean $\pm$ SD	Range	N	Mean $\pm$ SD	Range
<b>DML (% of ULN)</b>						
Median	13	155.5 $\pm$ 20.4*	127.8 - 186.1	9	257.4 $\pm$ 25.9	222.2 - 300
Ulnar	13	132.1 $\pm$ 21.7*	99.6 - 159.4	11	244.5 $\pm$ 39.5	167.3 - 298.8
Peroneal	12	120.6 $\pm$ 31.4*	96.2 - 209	4	253.7 $\pm$ 17.8	242.7 - 278.2
Posterior tibial	12	106.8 $\pm$ 20.1*	76.3 - 142.9	4	285.7 $\pm$ 17.8	264.2 - 307.2
<b>MNCV (% of LLN)</b>						
Median	13	106.8 $\pm$ 15.9	88.1 - 134.1	9	44.4 $\pm$ 6.6	38 - 59
Ulnar (BE-W)	13	95.9 $\pm$ 9.9 <sup>†</sup>	85 - 118.6	11	40.4 $\pm$ 11.7	29.4 - 68
Ulnar (AE-BE)	13	80 $\pm$ 9.3 <sup>†</sup>	67 - 105.1	9	29.9 $\pm$ 5.8	22.2 - 38.5
Peroneal (BFH-A)	11	97.4 $\pm$ 6.1 <sup>†</sup>	83.6 - 103.7	4	39.9 $\pm$ 1.5	38.2 - 41.6
Peroneal (AFH-BFH)	11	75.9 $\pm$ 21.3 <sup>‡</sup>	51.1 - 107.4	4	38.4 $\pm$ 1.7	36 - 39.6
Posterior tibial	12	97.4 $\pm$ 9.6	83.7 - 113.2	4	45.5 $\pm$ 5.9	39.4 - 51.7
<b>TLI</b>						
Median	13	0.17 $\pm$ 0.03	0.12 - 0.21	9	0.24 $\pm$ 0.02	0.21 - 0.29
ulnar	13	0.32 $\pm$ 0.04	0.26 - 0.4	11	0.42 $\pm$ 0.07	0.29 - 0.52
Peroneal	11	0.35 $\pm$ 0.06	0.23 - 0.41	4	0.39 $\pm$ 0.04	0.35 - 0.43
Posterior tibial	12	0.48 $\pm$ 0.08	0.34 - 0.6	4	0.38 $\pm$ 0.04	0.32 - 0.41
<b>CMAP (mV)</b>						
Median	13	11.9 $\pm$ 2.5	7.6 - 17.2	9	3.3 $\pm$ 1.5	0.9 - 5.0
Ulnar	13	13.8 $\pm$ 2.6	10.8 - 19.5	11	3.5 $\pm$ 1.8	1.2 - 6.4
Peroneal	12	5.6 $\pm$ 3.5	1.3 - 13.8	4	1.0 $\pm$ 0.3	0.7 - 1.3
Posterior tibial	12	14.6 $\pm$ 6.1	8.1 - 30	4	5.9 $\pm$ 1.6	4.0 - 8.0
<b>SNCV (% of LLN)</b>						
Median	13	74.2 $\pm$ 8.1 <sup>§</sup>	63 - 89.7	4	51.2 $\pm$ 7.1	41.2 - 60.6
Ulnar	13	78.2 $\pm$ 13.7 <sup>§</sup>	58.6 - 101.9	2	47.3 $\pm$ 6.6	38.8 - 59.3
Sural	13	88.7 $\pm$ 5.8 <sup>§</sup>	77.9 - 98	0	48.3 $\pm$ 1.0	38.8 - 60.6
<b>SNAP (<math>\mu</math>V)</b>						
Median	13	11.6 $\pm$ 5.5	5.8 - 21.6	4	6.5 $\pm$ 1.3	5.0 - 8.0
Ulnar	13	12.3 $\pm$ 8.2	4.1 - 34	2	6.3 $\pm$ 1.8	5.0 - 7.5
Sural	13	16.6 $\pm$ 8.7	7.7 - 40.7	0		

\*, §  $p < 0.01$ , Kruskal-Wallis test.

<sup>†</sup>, <sup>‡</sup>  $p < 0.01$ , Mann-Whitney test

N, number of examined nerves; DML, distal motor latency; MNCV, motor nerve conduction velocity; TLI, terminal latency index; CMAP, compound muscle action potential; SNCV, sensory nerve conduction velocity; SNAP, sensory nerve action potential; BE, below elbow; AE, above elbow; W, wrist; BFH, below fibular head; AFH, above fibular head; A, ankle

가 . CMT1A 가

가 . F 28

CMT1A , HNPP

(68 %), HNPP

(12 %).

가 , CMT1A

가 , MNCV SNCV

가 , 가

3,6,7,8 , 가

HNPP 5 가

가 (20%) HNPP

가 (sporadic) 20%

78% de novo

(asymptomatic carriers) .<sup>13</sup>

HNPP Anderson HNPP

가 가

2 .<sup>8</sup> HNPP

(focal entrapment

HNPP neuropathy)

, HNPP

HNPP

가 , HNPP

HNPP 가 CMT1A

HNPP (i.e., the carpal tun-

HNPP 가 nel, Guyon's canal respectively), SNCV DML가

(polyneuropathy)

CMT1A HNPP

.<sup>5,18</sup> , (e.g. sural nerve, peroneal nerve and posterior

HNPP (conduction block) tibial nerve)

(2%) . HNPP (Myelinopathy)

가 6~22%

HNPP 가

(submaximal stimula- tion at proximal sites)<sup>4,5,19</sup>

HNPP

가 , 가 (e.g. elbow

HNPP sites in ulnar nerve, fibular head in peroneal

HNPP TLI nerve)

가 , CMT1A

HNPP

가 HNPP  
가

REFERENCES

(subclinical) (compres  
sion neuropathy) HNPP  
HNPP  
가  
(peripheral myelin protein 22) (compact  
myelin sheath) PMP22  
HNPP (subclinical)  
(myelinopathy)  
(neurofilament) (phos-  
phorylation) (anterograde axonal transport)  
<sup>21,22,23</sup>  
(axonal degeneration)  
HNPP  
가  
temporal dispersion) (abnormal  
HNPP  
가  
가  
CMT1A HNPP  
HNPP CMT1A  
HNPP

1. Windebank AJ. Inherited focal neuropathies. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, eds. *Peripheral Neuropathy*. 3<sup>rd</sup> ed. Philadelphia: Saunders, 1993: 1137-1148.
2. Chance PF, Abbas N, Lensch MW, et al. Two autosomal dominant neuropathies result from reciprocal DNA duplication/deletion of a region on chromosome 17. *Hum Mol Genet* 1994;3:223-228.
3. Verhagen WIM, Gabreels-Festen AAWM, van Wensen PJM et al. Hereditary neuropathy with liability to pressure palsies: a clinical, electroneurophysiological and morphological study. *J Neurol Sci* 1993;116:176-184.
4. Gouider R, LeGuern E, Gugenheim M et al. Clinical, electrophysiologic and molecular correlations in 13 families with hereditary neuropathy with liability to pressure palsies and a chromosome 17p11.2 deletion. *Neurology* 1995;45:2018-2023.
5. Uncini A, Di Guglielmo, Di Muzio et al. Differential electrophysiological features of neuropathies associated with 17p11.2 deletion and duplication. *Muscle Nerve* 1995;18: 628-635.
6. Amato AA, Gronseth GS, Callerm KJ, Kagan-Hallet KS, Bryan W, Barohn RJ. Tomaculous neuropathy: a clinical and electrophysiological study in patients with and without 1.5Mb deletions in chromosome 17p11.2. *Muscle Nerve* 1996;19:16-22.
7. Cruz-Martinez A, Bort S, Arpa J, Duarte J, Palau F. Clinical, genetic and electrophysiologic correlation in hereditary neuropathy with liability to pressure palsies with involvement of PMP22 gene at chromosome 17p11.2. *Eur J Neurol* 1997;4:274-286.
8. Andersson PB, Yuen E, Parko K, So YT. Electrodiagnostic features of hereditary neuropathy with liability to pressure palsies. *Neurology* 2000;54:40-44.
9. Stewart JD. Compression and entrapment neuropathies, in Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF (eds): *Peripheral Neuropathy*. 3<sup>rd</sup> ed. Philadelphia, Saunders, 1993, pp 961-979.
10. Pareyson D, Scaiola V, Taroni F et al. Phenotypic heterogeneity in hereditary neuropathy with liability to pressure palsies associated with chromosome 17p11.2-12 deletion. *Neurology* 1996;46:1133-1137.
11. Mouton P, Tardieu S, Gouider R et al. Spectrum of clinical and electrophysiologic features in HNPP patients with the 17p11.2 deletion. *Neurology* 1999;52:1440-1446.
12. Sessa M, Nemni R, Quattrini A, Del Carro U, Wrabetz L, Can al N. Atypical hereditary neuropathy with liability to pressure palsies (HNPP): the value of direct DNA diagnosis. *J Med Genet* 1997;34:889-892.
13. Infante J, Garcia A, Combarros O et al. Diagnostic strategy for familial and sporadic cases of neuropathy associated

Acknowledgements

We are grateful to Hyun-Jung Kim for technical assistance.

- with 17p11.2 deletion. *Muscle Nerve* 2001;24:1149-1155.
14. Olney RK. Consensus criteria for the diagnosis of partial conduction block. *Muscle Nerve*. 1999;22(suppl 8);S225-S229.
  15. Oh SJ. Normal values for common nerve conduction tests. In: Oh SJ et al., eds. *Clinical electromyography-nerve conduction studies*. 2<sup>nd</sup> ed. Baltimore: Williams & Wilkins, 1993: 84-104.
  16. Shahani BT, Young RR, Potts F, Maccabee P. Terminal latency index (TLI) and late response studies in motor neuron disease (MND), peripheral neuropathies, and entrapment syndromes [Abstract]. *Acta Neurol Scand* 1979; Suppl 73:118.
  17. Haupt A, Schols L, Przuntek H, Epplen JT. Polymorphisms in the PMP-22 gene region (17p11.2-12) are crucial for simplified diagnosis of duplications/deletions. *Hum Genet*. 1997;99:688-691.
  18. Kaku DA, Parry GJ, Malamut R, Lupski JR, Garcia CA. Uniform slowing of conduction velocities in Charcot-Marie-Tooth polyneuropathy type I. *Neurology* 1993;43: 2664-2667.
  19. Sellman MS, Mayer RF. Conduction block in hereditary neuropathy with liability to pressure palsies. *Muscle Nerve* 1987;10:621-625.
  20. Schenone A, Nobbio L, Caponnetto C et al. Correlation between PMP-22 messenger RNA expression and phenotype in hereditary neuropathy with liability to pressure palsies. *Ann Neurol* 1997;42:866-872.
  21. DeWaegh S, Brady ST. Altered slow axonal transport and regeneration in a myelin-deficient mutant mouse: the trembler as an in vivo model for schwann cell-axon interactions. *J Neurosci* 1990;1885-1865.
  22. DeWaegh SM, Lee VMY, Brady ST. Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating schwann cells. *Cell* 1992; 68:451-463.
  23. Cole JS, Messing A, Trojanowski JQ, Lee VMY. Modulation of axon caliber and neurofilaments by hypomyelinating schwann cells in transgenic mice. *J Neurosci* 1994;14:6956-6966.
  24. Bjartmar C, Yin X, Trapp BD. Axonal pathology in myelin disorders. *J Neurocytol* 1999;28:383-395.